MDGL
Madrigal Pharmaceuticals Inc.
$524.30
+$4.55(+0.88%)
49
Overall
40
Value
66
Tech
42
Quality
Market Cap
$11.74B
Volume
268.89K
52W Range
$265.00 - $615.00
Target Price
$653.63
Company Overview
| Mkt Cap | $11.74B | Price | $524.30 |
| Volume | 268.89K | Change | +0.88% |
| P/E Ratio | -25.2 | Open | $516.96 |
| Revenue | $180.1M | Prev Close | $519.75 |
| Net Income | $-465.9M | 52W Range | $265.00 - $615.00 |
| Div Yield | N/A | Target | $653.63 |
| Overall | 49 | Value | 40 |
| Quality | 42 | Technical | 66 |
No chart data available
About Madrigal Pharmaceuticals Inc.
Madrigal Pharmaceuticals, Inc., a biopharmaceutical company, focuses on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH) in the United States. The company offers Rezdiffra, a liver-directed thyroid hormone receptor beta agonist for treating MASH. The company is headquartered in West Conshohocken, Pennsylvania.
Sector: Healthcare
Industry: Biotechnology
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | MDGL | $524.30 | +0.9% | 268.89K |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |
Get Madrigal Pharmaceuticals Inc. Data in Excel
Stream real-time data directly to your spreadsheets
BUY NOW